Inactive Instrument

News Protalex, Inc.

Equities

PRTX

US7436422098

Summary

Unlock all the news: Be the first to know and act before the market!

Protalex, Inc. Announces Management Resignations	18-11-30	CI
Protalex Plans To Raise Funds	18-10-12	CI
Protalex, Inc. Announces Data Highlighting Results from European Phase 1b of PRTX-100 in Patients with Immune Thrombocytopenia	18-06-15	CI
Protalex, Inc. Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in Mouse Model of Myasthenia Gravis	18-06-12	CI
Protalex, Inc. Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia	18-04-09	CI
Protalex, Inc. announced that it has received $1.43 million in funding	18-02-27	CI
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia	18-01-18	CI
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP	17-11-13	CI
Protalex, Inc. Announces Preclinical Data of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia	17-10-26	CI
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP	17-08-29	CI
Protalex, Inc. Announces Completion of Escalating the U.S. Phase 1/2 Study of PRTX-100 in Adults	17-08-01	CI
Protalex, Inc. Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia	17-02-21	CI
Protalex, Inc. Enters Amendment to Credit Facility	16-07-07	CI
Protalex Inc. Receives Positive Interim Review from Independent Safety Monitoring Committee in its European Phase 1B Study of PRTX-100 to Treat Immune Thrombocytopenia	16-05-02	CI
Protalex Announces Preliminary Findings from Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients	16-04-25	CI
Protalex Announces Interim Review of its U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia	16-02-29	CI
Protalex, Inc. Announces First Patient Dosed in European Phase Ib Study of PRTX-100 for Immune Thrombocytopenia	16-01-07	CI
Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France	15-10-05	CI
Protalex, Inc. to Initiate Enrollment of U.S. Phase I/II Trial of PRTX-100 to Treat Immune Thrombocytopenia	15-09-03	CI
Protalex, Inc. Auditor Raises 'Going Concern' Doubt	15-07-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Protalex, Inc.

Equities

PRTX

US7436422098

Summary

Filters